1-4 of 4
Daniel M. Sze
Close
Sort by
Journal Articles

Gene Expression Profiles of the Clinically Significant "Late" Stage Expanded Cytotoxic T Cells in Myeloma.

Tetsuo Yamagishi, BSc, Warren Kaplan, PhD, Devanshi Seth, PhD, Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 3418.
https://doi.org/10.1182/blood.V106.11.3418.3418
Published: 2005
Journal Articles

Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.

Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, PhD, John Gibson, PhD, Douglas E. Joshua, PhD, Winfried Wels, PhD, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 5104.
https://doi.org/10.1182/blood.V106.11.5104.5104
Published: 2005
Journal Articles

The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.

Ross D. Brown, PhD, Allan Murray, Daniel M. Sze, PhD, Andrew Spencer, MD, Phoebe Joy Ho, MD, John Gibson, MD, Douglas E. Joshua, MD
Journal: Blood
Blood (2005) 106 (11): 5108.
https://doi.org/10.1182/blood.V106.11.5108.5108
Published: 2005
Journal Articles

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β 1 and interleukin-10

Ross D. Brown, Belinda Pope, Allan Murray, Warren Esdale, Daniel M. Sze, John Gibson, P. Joy Ho, Derek Hart, Doug Joshua
Journal: Blood
Blood (2001) 98 (10): 2992–2998.
https://doi.org/10.1182/blood.V98.10.2992
Published: 2001